Disclosures Norman Zinner has acted as a consultant and/or speaker or conducted research for Allergan, Astellas, Eli Lilly, Esprit, GlaxoSmithKline, Indevus, Novartis, Pfizer and Watson. Kathleen C. Kobashi has acted as a consultant and/or speaker or conducted research for Novartis, Astellas and Coloplast. Ursula Ebinger and Andrea Viegas are employees of, and own shares in, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Mathias Egermark and Erhard Quebe-Fehling are employees of, and own shares in, Novartis Pharma AG, Basel, Switzerland. Pat Koochaki is an employee of Procter and Gamble Pharmaceuticals Corporation, Cincinnati, OH, USA.
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
Article first published online: 22 SEP 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 62, Issue 11, pages 1664–1674, November 2008
How to Cite
Zinner, N., Kobashi, K. C., Ebinger, U., Viegas, A., Egermark, M., Quebe-Fehling, E. and Koochaki, P. (2008), Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. International Journal of Clinical Practice, 62: 1664–1674. doi: 10.1111/j.1742-1241.2008.01893.x
Study registered at: http://www.clinicaltrials.gov (reference NCT00366002).
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
- Issue published online: 15 OCT 2008
- Article first published online: 22 SEP 2008
- Paper received April 2008, accepted July 2008
- 2Darifenacin is selective for the human recombinant M3 receptor subtype (abstract). http://www.icsoffice.org/publications/2002/pdf/445.pdf (accessed 27 August 2008)., .
- 8Solifenacin reduces overactive bladder symptoms and improves health-related quality of life in patients previously treated with tolterodine (abstract). http://www.icsoffice.org/publications/2006/pdf/0332.pdf (accessed 12 January 2007)., , .
- 9Antimuscarinic therapy for overactive bladder syndrome: possible benefits of switching to solifenacin (abstract). http://www.icsoffice.org/publications/2005/pdf/0571.pdf (accessed 21 May 2008)., , .
- 12FDA Report. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf (accessed 27 August 2008).